Status: Recruiting
Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL
To evaluate the efficacy of celecoxib combined with R-CHOP versus R-CHOP in the treatment of newly diagnosed advanced CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).The primary endpoint is Complete Response Rate (CRR)
Participants needed: 60
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Jul 22, 2026Locations: 1
Eligibility criteria
Age ≥ 18 years and ≤ 80 years, either gender, life expectancy > 6 months. [+11]
History of primary or secondary central nervous system (CNS) lymphoma or CNS lym... [+22]